ArticleFrontiers in oncology2025
An integrated clinicopathological and genomic model for personalized prognosis in stage II-III colorectal cancer: a real-world study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis for patients with stage II-III colorectal cancer (CRC) is heterogeneous, with only a subset benefiting from adjuvant chemotherapy. Currently, prognostic models that effectively integrate clinicopathological and genetic factors remain limited. This study aimed to develop a predictive model that accurately forecasts survival and guides personalized treatment decisions. Methods: Data from 322 CRC patients were analyzed. Significant prognostic factors were selected using univariate Cox regression analysis. Subsequently, the least absolute shrinkage and selection operator (LASSO) regression algorithm, coupled with the Cox proportional hazards model, was applied to identify the most parsimonious set of predictors. A nomogram was constructed based on a multivariable Cox regression model to estimate 3- and 5-year overall survival (OS). Predictive performance was assessed using the concordance index (C-index), receiver operating characteristic (ROC) curve analysis, and calibration plots. Decision curve analysis (DCA) was performed to assess the clinical utility of the nomogram. Results: Multivariate analysis identified tumor stage, tumor differentiation grade, lymphovascular invasion, BRAF mutation, and adjuvant chemotherapy as independent predictors of OS. The developed nomogram demonstrated good discrimination, with a C-index of 0.712 and 0.726 for the training and testing cohorts, respectively. Calibration plots showed excellent agreement between predicted and observed 3- and 5-year OS. DCA confirmed that the nomogram provided clinical net benefits. Conclusion: The nomogram, integrating clinicopathological and genetic factors, provides a robust tool for predicting outcomes in patients with stage II-III CRC. It can aid in personalized treatment planning and improve patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.